The price of HOOKIPA Pharma Inc. (NASDAQ:HOOK) shares last traded on Wall Street fell -0.01% to $1.00.
Based on available information, 8 analysts follow HOOKIPA Pharma Inc. (NASDAQ:HOOK). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $11.00 and a low of $0.50, we find $5.00. Given the previous closing price of $1.00, this indicates a potential upside of 400.0 percent. HOOK stock price is now 5.78% away from the 50-day moving average and -27.77% away from the 200-day moving average. The market capitalization of the company currently stands at $55.79M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Among analysts, 1 rate the stock a hold while 6 rate it a buy. Brokers who have rated the stock have averaged $5.31 as their price target over the next twelve months.
With the price target maintained at $0.50, BofA Securities recently Downgraded its rating from Buy to Underperform for HOOKIPA Pharma Inc. (NASDAQ: HOOK)., while ‘Morgan Stanley’ rates the stock as ‘Equal-Weight’.
A total of 8.15% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in HOOK stock. A new stake in HOOKIPA Pharma Inc. shares was purchased by ACADIAN ASSET MANAGEMENT LLC during the first quarter worth $73,000. TWO SIGMA INVESTMENTS, LP invested $38,000 in shares of HOOK during the first quarter. In the first quarter, CHARLES SCHWAB INVESTMENT MANAGEMENT INC acquired a new stake in HOOKIPA Pharma Inc. valued at approximately $36,000. CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. acquired a new stake in HOOK for approximately $22,000. MAN GROUP PLC purchased a new stake in HOOK valued at around $10,000 in the second quarter. In total, there are 82 active investors with 62.90% ownership of the company’s stock.
A candlestick chart of HOOKIPA Pharma Inc. (NASDAQ: HOOK) showed a price of $1.0500 on Monday morning. During the past 12 months, HOOKIPA Pharma Inc. has had a low of $0.72 and a high of $3.05. As of last week, the company has a debt-to-equity ratio of 0.03, a current ratio of 5.00, and a quick ratio of 5.00. The fifty day moving average price for HOOK is $0.9453 and a two-hundred day moving average price translates $1.3843 for the stock.
The latest earnings results from HOOKIPA Pharma Inc. (NASDAQ: HOOK) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.23, beating analysts’ expectations of -$0.36 by 0.13. This compares to -$0.61 EPS in the same period last year. The company reported revenue of $2.23 million for the quarter, compared to $3.87 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -42.44 percent. For the current quarter, analysts expect HOOK to generate $2.91M in revenue.
HOOKIPA Pharma Inc.(HOOK) Company Profile
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company’s preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
